Express Scripts (ESRX) Mylan Selloff Is Overdone - Jefferies

August 26, 2016 8:04 AM EDT
Get Alerts ESRX Hot Sheet
Price: $69.61 -2.01%

Rating Summary:
    11 Buy, 16 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ESRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, Brian Tanquilut believes the pressure on Express Scripts (NASDAQ: ESRX) due to concerns about potential pricing scrutiny for players in the drug supply chain, including the PBMs and retail pharmacies is overdone. The analyst believes that the PBMs enable health plan benefit sponsors to optimize costs through clinical programs, scale purchasing, and new tools/offerings such as inflation protection and cost trend guarantees, which he believes plan sponsors generally recognize.

No change to the Buy rating or price target of $88.

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $71.74 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment